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ABSTRACT
Pseudoxanthoma Elasticum (PXE) is a rare disorder characterized by fragmentation and 
progressive calcification of elastic fibres in connective tissues. Overlap has been reported between 
the inherited PXE phenotype associated with ENPP1, ABCC6 or NT5E mutations and acquired 
PXE clinical manifestations associated with haemoglobinopathies induced by HBB mutations. No 
treatment is available for PXE to date. A young boy presented with severe early-onset systemic 
calcifications occurring in the skin as elastosis perforans serpiginosa (EPS) and in the arteries 
causing mesenteric and limb ischemia.  Molecular and functional analyses revealed deleterious 
ABCC6, ENPP1 and HBB mutations. The diagnosis of severe PXE was retained and we coined the 
term of “PXE+ syndrome” to report the cumulative effects of the various mutations in this 
uncommon phenotype. Given severity, rapid progression and a potentially fatal prognosis, 
intravenous sodium thiosulfate (STS) was initiated at 25g 3-times/week for six months. Numerous 
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months. Asthenia, anorexia and pre/post prandial pain had completely subsided entailing weight 
gain. Abdominal EPS had diminished. Calcific stenosis of the celiac and mesenteric arteries was 
no longer detectable on arterial ultrasonography. Follow-up however revealed only transient 
efficacy of STS. Discontinuation of treatment to evaluate persistence of effects resulted in relapse 
of initial symptomatology after four months. STS efficacy is conceivably due to strong 
antioxidant properties and chelation of calcium to form soluble calcium thiosulfate complexes. 
This case is suggestive of PXE+ syndrome for which STS may represent potential treatment in 
severe cases.
What is already known about this topic?
• Generalized arterial calcification of infancy (GACI) may occur in association with ABCC6 
mutations and pseudoxanthoma elasticum (PXE) can be linked to ENPP1 mutations. 
• A PXE-like phenotype has also been reported in a subset of patients with inherited 
hemoglobinopathies, namely sickle cell disease or β-thalassemia related to beta-globin (HBB) 
gene mutations.
• To date there is still no cure for PXE.
What does this study contribute?
• We report a severe case of PXE resulting from the cumulative effects of several deleterious 
mutations in the ENPP1, ABCC6 and HBB genes. We suggest to coin the term “PXE+ 
syndrome” to qualify such patients.
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INTRODUCTION
Pseudoxanthoma Elasticum (PXE, OMIM #264800) is an autosomal recessive metabolic disorder 
characterized by the fragmentation and progressive calcification of elastic fibres in connective 
tissues such as the skin, vascular system and Bruch’s membrane of the retina1. PXE is caused by 
mutations in the ABCC6 gene which encodes a transmembrane ATP-binding cassette (ABC) 
transporter primarily expressed in the liver and kidney2. ABCC6 endogenous substrates are 
unknown but pyrophosphate (PPi) deficiency reliably accounts for remote calcification3,4. Typical 
PXE manifestations include yellowish papules on the neck and in large skin folds, loss of central 
vision and cardiovascular complications such as peripheral artery disease (PAD)1. Mutations in 
ENPP1, encoding ectonucleotide pyrophosphatase/phosphodiesterase 1 (NPP1), were found to 
cause generalized arterial calcification of infancy (GACI, OMIM #208000)5.
In this disorder, calcification in the media of large- and medium-sized arteries is associated with 
intimal proliferation leading to arterial stenosis. Phenotype and genotype overlapping between 
GACI and PXE has been reported6. Recently, a phenotype resembling arterial calcification due to 
deficiency of CD73 (ACDC, OMIM #211800) commonly linked to ecto-5'-nucleotidase (NT5E) 
mutations was reported in a carrier of two ABCC6 mutations7. A PXE-like phenotype has also 
been reported in a subset of patients with inherited hemoglobinopathies such as sickle cell disease 
(SCD, OMIM #603903)8 or β-thalassemia (OMIM #613985)9 related to beta-globin (HBB) gene 
mutations9. 
To date a cure for PXE has yet to be found. In the present case report, we illustrate improvement 
following sodium thiosulfate treatment (STS) in the condition of a young PXE boy with a complex 
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CASE REPORT
An 11-year-old boy from sub-Saharan Africa was referred for management of symptomatic PAD, 
retinal angioid streaks and cutaneous lesions. On admission, symptomatology included asthenia, 
anorexia, weight loss of 10 kg, intermittent claudication and pre/postprandial abdominal pain 
presumably due to mesenteric angina. Examination revealed widespread yellowish papules in the 
large folds and papular lesions in the abdominal area suggestive of elastosis perforans serpiginosa 
(Figure 1; Panels 1&2). Histological analysis of skin biopsy showed short curled elastic fibres in 
the reticular dermis (Figure 2; Panels 1&2) and calcified elastic fibres on Von Kossa staining 
(Figure 2; Panel 3). Fundus examination revealed “peau d’orange” and peripheral angioid streaks 
with no haemorrhagic complications. Ankle-brachial index was <0.6 (N=0.9-1.3) confirming the 
diagnosis of PAD. Arterial ultrasonography revealed widespread medial calcific sclerosis 
extending from the abdominal aorta to the distal lower limb arteries with severe (>70%) stenosis 
in the celiac, superior mesenteric and superficial femoral arteries (Figure 5; Panels 1&2). Blood 
tests yielded no acute inflammation (hsCRP<1mg/l) and normal phosphorus/calcium levels. Non-
iron deficient microcytic anemia was detected and haemoglobin electrophoresis revealed 40% 
haemoglobin S; 3.3% haemoglobin A2; and 56.7% haemoglobin A0 consistent with heterozygous 
sickle-cell disease, which was molecularly confirmed by one heterozygous mutation in the HBB 
gene p.(Glu7Val ).
Molecular analysis of the ABCC6 gene (direct sequencing of the complete coding region and the 
intron-exon boundaries, coupled with MLPA analysis) revealed the heterozygous pathogenic 
nonsense variant p.(Arg1141*);c.3421C>T. Direct sequencing of the coding region of the other 
PXE-related genes (ENPP1, GGCX) demonstrated two previously unreported biallelic 
heterozygous ENPP1 missense variants: p.(Glu866Lys);c.2596G>A and 
p.(Cys711Tyr);c.2132G>A. Segregation analysis of ABCC6 and ENPP1 variants in the mother 
confirmed she carried only the ENPP1 p.(Cys711Tyr);c.2132G>A variant. The father was 
unwilling to participate in the segregation analysis. To determine the functional impact of the 
missense variants in ENPP110, we transfected a pcDNA3.1(+) expression vector harbouring the 
mutated full-length ENPP1 coding sequence into the human embryonic kidney (HEK293) cells 
and measured NPP activity (Figure 3; Panel 1). Cys711Tyr completely abolished NPP activity, 
whereas Glu866Lys showed residual but significantly reduced NPP activity to about 60% of that 
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WT ENPP1). Both mutant proteins were expressed similarly to the WT protein (Figure 1; Panel 
2). We tested whether extracellular PPi generation was affected by the variants in ENPP1. PPi 
levels in the medium of HEK293 cells transfected with WT ENPP1 increased rapidly over time 
(Figure 3; Panel 3). In the medium of HEK293 cells expressing the Cys711Tyr and Glu866Lys 
mutants, PPi levels were not different from the PPi levels in the medium of HEK293 cells 
transfected with the empty vector (p>0.3 vs. empty vector, p<0.005 vs. WT ENPP1, after 20 min) 
(Figure 3; Panel 3). Each mutant was individually expressed in Cercopithecus aethiops kidney 
(COS7) cells. WT ENPP1 was found predominantly in the plasma membrane (Figure 4). The 
ENPP1 mutant Cys711Tyr when expressed in COS7 cells demonstrated intracellular localization 
instead of WT-like cellular localization in the plasma membrane (Figure 4). The Glu866Lys 
mutant fully localized to the plasma membrane in the same manner as WT ENPP1 (Figure 4). 
Given the severity of the phenotype, its rapid progression and an extremely unfavourable, 
potentially fatal prognosis, intravenous (IV) STS was initiated at a dose of 25g 3-times/week for 
six months, resulting in impaired quality of life with numerous side effects including metabolic 
acidosis, vomiting and dizziness7. This prompted dosage adjustment to 10g IV/day8. Efficacy of 
STS was evaluated at six-month follow-up. Infiltration of the papular lesions on the abdomen had 
diminished (Figure 1; Panel3). Asthenia, anorexia and pre/post prandial pain had completely 
subsided and the patient had gained weight (+10kgs). On arterial ultrasonography, calcific stenosis 
of the celiac and mesenteric arteries had disappeared (Figure 5; Panels 3&4). Discontinuation of 
treatment to evaluate persistence of effects resulted in exacerbation of symptoms such as digestive 
angina, lower limb claudication and relapse of abdominal skin changes after four months. STS 
was resumed.
DISCUSSION
According to 2014 criteria11, PXE diagnosis requires either two pathogenic ABCC6 mutations or a 
combination of ocular findings (retinal angioid streaks > 1 Disc Diameter (DD) or “peau d'orange” 
in individuals aged <20) together with characteristic skin findings (pseudoxanthomatous 
papules/plaques on the neck or in flexural creases or diagnostic histopathological changes in 
lesional skin)11. In the present case report, although clinical diagnosis criteria for PXE were met, 
molecular analysis revealed a single heterozygous nonsense variant in the ABCC6 gene in addition 
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HBB gene. We confirmed that both Cys711Tyr and Glu866Lys variants led to loss-of-function in 
the NPP1 protein, most likely due to impaired stability and/or conformation5,10. Moreover, our 
patient had SCT. A link between β-thalassemia or sickle cell disease (SCD) and PXE was first 
reported in 1964 and 1989, respectively9. The pathophysiology is still poorly understood8,9,12,13. 
Although histological changes similar to those found in PXE have been demonstrated in patients 
with β-thalassemia, studies have failed to reveal any abnormality in the ABCC6 gene in these 
patients, strongly implying that it is an acquired rather than inherited form of PXE14. This was 
demonstrated in a mouse model of β-thalassemia where a liver-specific down-regulation of Abcc6 
expression was observed15. The most widely accepted hypothesis revolves around oxidative 
damage to elastic tissue, while other theories evoking neutrophil elastase activity-related elastic 
degradation are less substantiated9,16. suggests that all genes producing PXE-like manifestations 
should be screened in patients with SCD, β-thalassemia  and PXE findings8. We speculate that the 
severe early-onset PXE phenotype of our patient could result from the cumulative effects of 
several deleterious mutations in the ENPP1, ABCC6 and HBB genes and as a result we would like 
to coin the term “PXE+ Syndrome” to better individualize this condition.
STS proved to be transiently effective in improving calcified cutaneous and vascular lesions in our 
PXE+ phenotype patient. STS therapy was adopted by virtue of its similarity to uremic and non-
uremic calciphylaxis7,13. STS chelates divalent cations and possesses antioxidant and vasodilatory 
properties7,13,14. Its chelating action has been used in non-uremic patients with renal lithiasis to 
increase the solubility of deposits or calcium crystals, or to dissolve ectopic calcifications in blood 
vessels13. STS is also a reducing agent, thus enabling regeneration of the oxidized glutathione 
involved in cellular detoxification mechanisms. Moreover, chronic ischemia induces reactive 
oxygen species (ROS) and causes depletion of tetrahydrobiopterin, an essential cofactor in nitric 
oxide (NO) synthesis17. Consequently, STS restores endothelial function, NO production and 
enables vasodilation. It is believed to increase calcium phosphate solubility in soluble thiosulphate 
complexes7. This chelating effect of calcium appears to have longer action time of up to a 
month14, as confirmed by cutaneous/vascular findings from our case report at 6-months post STS 
therapy. With respect to the multi-factorial positive effects observed in terms of calcium chelation, 
oxidative-stress and vasodilation, and despite the complexity of its treatment protocol and its 
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